NLRP3 and diabetic kidney disease: Breviscapine (Bre), exerting a renoprotective effect, alleviated podocyte injury by decreasing α-smooth muscle actin (α-SMA) expression, increasing podocin and synaptopodin expression, and in part inhibiting NF-κB/NLRP3-mediated pyroptosis in DKD [60].